DMD #48918
Nonstandard abbreviations: ABC = ATP-binding cassette; A→B = Apical to basolateral; BCRP = human breast cancer resistance protein; B→A = Basolateral to apical; B→A/A→B ratio = P app B→A /P app A→B ; BNF = β-naphthoflavone; CHO = Chinese hamster ovary cell line; CL i = intrinsic clearance; CYP = cytochrome P450; DTG= dolutegravir (S/GSK1349572; (4R,12aS)-N-(2,4-Difluorobenzyl) -7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5] (e.g., highly active antiretroviral therapy; HAART) has resulted in very low to undetectable HIV RNA in serum, patients living longer and fewer dying from the disease [Palella et al., 1998; Palella et al., 2006] . This outcome changes the focus of HIV therapy from one mainly focused on managing the viral disease to one of also considering other co-morbidities, including the treatment of an aging HIV population with conditions such as cardiovascular disease and diabetes. Thus, as newer HIV agents come to market, the drug-drug interaction (DDI) assessment needs to include a broader number of co-medications than previously considered for the treatment of HIV disease.
Management of DDIs in HIV subjects is challenging because the major mechanisms of DDIs in antiretroviral combination therapy involve CYP enzymes, ATP-binding cassette efflux transporters, and solute carrier uptake transporters [Zembruski et al., 2011a] . Most PIs (e.g. lopinavir, fosamprenavir, darunavir) are substrates or inhibitors of CYP3A4, and many of these agents require boosting with ritonavir, a very potent CYP3A4 inhibitor [Hull and Montaner, This article has not been copyedited and formatted. The final version may differ from this version. other antiviral drugs such as atazanavir are potent inhibitors of both CYP3A4 and UDPglucuronosyltransferase 1A1 (UGT1A1) [Zhang et al., 2005] . Enzyme inhibition is not the only DDI concern, as potent CYP3A4 inducers, such as NNRTIs etravirine and efavirenz, can increase the metabolism of co-administered drugs resulting in reduced exposure and efficacy [Yanakakis and Bumpus, 2012; Hariparsad et al., 2004] . Finally, to add to the complexity, a single agent such as ritonavir can simultaneously be a potent inhibitor of one pathway (e.g.,
CYP3A4
) and a potent inducer for another (e.g., CYP2C19) [Yeh et al., 2006] .
In addition to metabolic enzymes, drug transporters can influence antiviral drug disposition.
Protease inhibitors are transported by efflux transporters such as Pgp, BCRP and MRP2 and the OATP uptake transporters [Dixit et al., 2007] . Co-administration of Pgp or BCRP inhibitors, such as ritonavir or saquinavir, may increase the oral absorption of an HIV co-medication that is a substrate for these transporters, or allow entry into more restricted tissues such as the brain or placenta. Alternatively, absorption can be reduced via induction of these transporters. Clinically significant Pgp interactions have been reported with the protease inhibitors tipranavir/ritonavir and the Pgp substrate loperamide resulting in a 50% reduction in the AUC of loperamide [Mukwaya et al., 2005] . Dolutegravir (DTG) is a tricyclic carbamoyl pyridone integrase inhibitor (INI) that blocks the strand transfer step during the integration of the HIV-1 DNA into the genome of the host cell.
The unique features of DTG include a superior resistance profile and once daily low milligram dosing that does not require pharmacokinetic boosting . Like other DMD #48918 7 antiretroviral agents, it is expected that DTG will be co-administered in combination with a wide variety of other drugs, including agents other than antivirals for non-HIV related co-morbidities.
Because of the potential overlapping transporter and metabolic pathways of DTG and drugs coadministered to treat HIV infection or other diseases, it is critical to evaluate the potential for clinical DDIs, especially in the HIV polypharmacy setting. Therefore the objective of this study was to investigate the mechanisms for the potential role of transporters and metabolizing enzymes in the disposition of DTG, to provide a basis for predicting when other drugs could result in a drug interaction with DTG, and when DTG might cause interactions with other coadministered drugs.
This article has not been copyedited and formatted. The final version may differ from this version. [Polli et al., 2001; Polli et al., 2008] at pH 7.4/7.4 in Dulbecco's Modified Eagle Medium (both donor and receiver sides), and at pH 5.5/7.4 or 7.4/7.4 using a bio-relevant buffer (FaSSIF, fasted state simulated intestinal fluid on the donor side and 1% human serum albumin on the receiver side) to simulate conditions in the gastrointestinal tract; pH 5.5 was selected as the lower pH because it provides a larger pH range that is reflective of the variability observed in the human and animal gastrointestinal tract [Evans et al., 1988; Lui et al., 1986] . The passive membrane permeability was determined in the presence of 3 μM GF120198, which was used to inhibit efflux pumps, and Lucifer yellow was included to verify monolayer integrity. . Drugs were quantified by liquid scintillation counting (LSC) using a TriCarb T2900 liquid scintillation counter and Ultima Gold scintillation cocktail (Perkin Elmer, Boston, MA).
Pgp and BCRP Inhibition Assays. Cell culture and transport studies were completed as described previously Rautio et al., 2006] Collection, Manassas, VA) transduced with BacMam baculovirus containing the human OATP1B3 transporter, were used for the OATP1B3 inhibition assay. Cell culture and inhibition studies were completed as described previously . DTG was tested in triplicate (0.3 to 100 µM) and rifamycin SV (10 µM) was used as a positive control inhibitor. inhibitor, azamulin, on the metabolism of DTG was evaluated by pre-incubating azamulin (5μM) with HLM (2mg/mL), 0.1M phosphate buffer, pH 7.4, and cofactor for 10min before adding Reactions were initiated with the addition of cofactor (an NADPH regenerating system consisting of 1 mM NADPH, 5.5 mM glucose-6-phosphate and 1.2 units/mL glucose-6-phosphate dehydrogenase) and terminated after 2hr by the addition of an equal volume of acetonitrile. Incubations were performed with no cofactor and with vector control membranes.
OCT
This article has not been copyedited and formatted. The final version may differ from this version. 1mg/mL protein) were conducted by activating the enzymes with alamethicin as described above. Reactions were started with UDPGA and incubations performed for 2 and 4 hours.
Control incubations were performed in the 1) absence of cofactor, and 2) with UGT insect cell control Supersomes™ (lacking UGT activity) (BD Gentest, Woburn, MA). The in vitro enzyme kinetic parameters were determined for glucuronide formation of [ 14 C]DTG (2.0, 5.0, 10, 25, 50, and 100 μM) in HLM and human UGT1A1 enzymes. Incubations were performed for 2 hours and processed as described previously.
HPLC Radiochemical profiling and metabolite identification.
Radiochemical profiles of human hepatocytes, HLM and recombinant CYP and UGT incubations were generated using an Agilent 1100 HPLC system (Palo Alto, CA, USA) coupled CYP inhibition by Dolutegravir. The potential for DTG to inhibit human CYP enzymes (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4) in a direct and metabolism-dependent manner was evaluated in HLM (0.1 mg/mL). Incubation conditions, analytical details positive control inhibitors and specific probe substrates for the CYP inhibition studies were conducted as described [Polli et al., 2012] . Incubations for DTG and positive control inhibitors were tested in duplicate (0.1 to 100 µM). To assess direct CYP inhibition, reactions were initiated by an NADPH regenerating system (cofactor solution consisting of 1.7mg of NADP + , 7.8mg of glucose-6-phosphate, and 6 units of glucose-6-phosphate dehydrogenase per mL). CYP This article has not been copyedited and formatted. The final version may differ from this version. [Polli et al., 2012] . Analyte (probe substrate metabolite) to internal standard peak area ratios were calculated and the metabolite concentrations were determined by interpolation from the individual standard curve. Rates of metabolite production at each concentration were expressed as a percentage of the mean uninhibited control rate for each assay.
Non-linear regression analysis of the data was performed using GraFit (v.5.0.8, Erithacus software, Limited, London) to calculate IC 50 values.
UGT inhibition by Dolutegravir. The ability of DTG to inhibit UGT1A1 and 2B7 was evaluated by measuring the glucuronidation of scopoletin (20μM; UGT1A1) and 7-hydroxy-4-(trifluoromethyl) coumarin (HFC; 15μM; UGT2B7) in UGT Supersomes™ (BD Gentest, Woburn MA) using fluorescence detection [Collier et al., 2000] . DTG (0. Following culture and test compound treatment cells were lysed and total RNA extracted. mRNA expression for each CYP was determined using quantitative real-time polymerase chain reaction technology (TaqMan™) [Bowen et al., 2000] . Relative differences in mRNA expression were assessed based on different cycling threshold (Ct) values which were determined by the ABI 7900 Real Time PCR System Sequence Detection Software (SDS v1.3).
Calculations.
For monolayer efflux studies, the flux of DTG and probe substrates was calculated using the following equation:
This article has not been copyedited and formatted. The final version may differ from this version. 
where J is the flux (nmol/cm 2 /h), V is the receptor volume (mL), C is the receiver drug concentration (nmol/ml), t is time in hours, and A is the membrane surface area (cm 2 ).
The passive permeability of DTG, probe substrates and Lucifer yellow in the presence of GF120918 was determined using the following equation as described previously [Rautio et al., 2006] :
x 10 7 nm/s where P 7.4 is the permeability coefficient at pH 7.4, V D , V R are donor and receiver well volumes, respectively (mL), A is the membrane surface area (cm 2 ), t is the incubation time (seconds), C R (t) is the measured concentration in the receiver well at time t (nmol/mL), C D (t) is the measured concentration in the donor well at time t (nmol/mL). For UGT1A1 enzyme kinetic determinations non-linear regression analysis of the ether glucuronide formation was performed using GraFit. Michaelis-Menten parameters V max , K m , and CL i were calculated using the following equations:
Where V max is maximal rate of metabolite produced, K m is equal to the substrate concentration at which the reaction rate is half its maximal value, [S] is the substrate concentration, and CL i is the intrinsic clearance.
In vitro-in vivo extrapolation of DTG as a victim of UGT1A1 and CYP3A4 inhibition
A mechanistic static equation based on previously described models [Hinton et al., 2008] was used to predict the magnitude of DTG exposure in vivo when co-administered with the clinically relevant UGT1A1 and CYP3A4 inhibitors, atazanavir and ritonavir: µM), were estimated according to methods previously described in the literature [Ito et al., 1998 ]. The atazanavir inhibition constants for UGT1A1 and CYP3A4 are K i,ATZ,UGT1A1 (0.2 µM) and Ki, ATZ,CYP3A4 (2.35 µM) , respectively [Busti et al., 2004] CYP3A4 and UGT1A1 are shown as K i,RTV,3A4 (0.03 µM) and K i,RTV,UGT1A1 (9.5 µM) [Granfors et al., 2006; Zhang et al., 2005] . The K i,RTV,UGT1A1 was estimated by dividing the reported IC 50 value in half, assuming competitive inhibition. F g , the fraction of substrate escaping gut-wall metabolism, was assumed to be 1 based on DTG's in vitro intrinsic clearance and high passive permeability. F m is the fraction of the substrate dose metabolized by a specific enzyme (e.g.,
CYP3A4 or UGT1A1).
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The inhibitory effect of DTG on human organic cation transporter 1 (OCT1) and 2 (OCT2) was investigated by measuring the uptake of [ 14 C]metformin in HEK293-OCT1 and MDCKII-OCT2 cells, respectively. DTG at 10μM slightly inhibited OCT1 transport by 22%. However, DTG notably inhibited the renal transporter OCT2 by 91% when tested at a concentration of 25μM.
Based on this observation, a study to determine the IC 50 value against OCT2 was completed.
DTG inhibited OCT2 with an IC 50 value of 1.9μM (Table 2, Figure 1 ). Figure 2B ). Further studies were done to determine the formation kinetics of the DTG glucuronide. The estimated kinetic parameters, K m , V max , and CL i , for M2 formation in HLM were 149μM, 409pmol/min/mg, and 2.7μL/min/mg, respectively ( Figure 3A) , and for the recombinant human UGT1A1 enzyme were 21μM, 67pmol/min/mg, and 3.2μL/min/mg, respectively ( Figure 3B ).
Identification of Enzymes
The oxidative metabolism of [ 14 C]DTG (5μM) was studied in NADPH-fortified HLM and recombinant CYP enzymes. An oxidative metabolite (M3) was formed in CYP3A4 incubations ( Figure 2C ) with an intrinsic clearance of 3.0 μL/min/mg. M3 was also observed in HLM incubations ( Figure 2C ) and its formation was completely inhibited by azamulin, a selective CYP3A4 inhibitor. In addition, an N-dealkylated metabolite (M1), which is a hydrolysis product of M3, was observed in the CYP3A4 incubations. No DTG metabolites were observed in CYP1A2, 2B6, 2C8, 2C9, 2C19, or 2D6 incubations indicating that CYP3A4 is the primary CYP enzyme involved in the oxidative metabolism of DTG in vitro. The overall metabolic profile for DTG is summarized in Figure 4 .
CYP and UGT Inhibition by Dolutegravir. The inhibition of human CYP enzymes by DTG
was evaluated using HLM and selective CYP probe substrates (Table 3) . DTG inhibited CYP2B6, 2C9, 2C19, 2D6 and 3A4 (nifedipine), but the percentage of inhibition observed (range 20 to 40%) at the highest concentration tested (100μM) was weak and insufficient to calculate an IC 50 . In contrast, DTG inhibited CYP3A4-mediated metabolism of atorvastatin with a calculated IC 50 of 54μM (Table 3) . DTG did not inhibit CYP1A2, 2A6, or 2C8 (IC 50 >100μM; 
Discussion
The studies presented herein describe the in vitro disposition and metabolism of DTG and the potential for DTG to be a victim or perpetrator of DDIs via modulation of transporters or metabolizing enzymes. Like other antiretroviral agents, DTG will be co-administered in combination with a variety of other drugs. Therefore, assessment of potential DDIs is an essential aspect in the clinical development of DTG.
Based on the limited aqueous solubility and high permeability, DTG is a Biopharmaceutics Drug Disposition Classification System class 2 drug [Benet et al., 2011; Benet et al., 2008] , where efflux transporters and metabolizing enzymes are predicted to be important in the drug's disposition. Indeed, in vitro studies show that DTG undergoes extensive metabolism and is a substrate for Pgp and BCRP, two transporters reported to influence the intestinal absorption and CNS penetration of HIV drugs [Kivisto et al., 2004] . Although DTG is a substrate for efflux transporters, it exhibits rapid oral absorption (T max ~2hr following a 50mg dose) and displays dose proportional kinetics with low to moderate variability . These data suggest that the high intrinsic passive membrane permeability attenuates any impact efflux transporters may have on DTG's intestinal absorption in humans. This is further supported by clinical studies that have demonstrated no clinically significant change in DTG pharmacokinetics when co-administration with lopinavir/ritonavir [Song et al., 2011d] , which are known Pgp and BCRP inhibitors.
In a human mass balance study where healthy subjects received 20 mg of 18.9% of total dose), N-dealkylation (M1, 3.6% of total dose), and a metabolite formed by oxidation at the benzylic carbon (M3, 3.0% of total dose) (GSK data on file). Fecal elimination contributed an additional 3.1%, resulting in approximately 10% of the metabolism of DTG being represented by oxidative products. Based on the fraction of the dose renally eliminated and the intrinsic clearance values determined from in vitro UGT and CYP3A4 studies, the fraction of DTG metabolized by UGT1A1 (f mUGT1A1 ) and CYP3A4 (f mCYP3A4 ) is estimated to be 0.51 and 0.21, respectively. The fraction of DTG metabolized by UGT1A3 and 1A9 is estimated at 0.028 and 0.055, respectively. It should be noted that the estimates of f mUGT may be underestimated due to the instability of the ether glucuronide in feces, as the conjugate may hydrolyze and convert back to parent drug under these conditions. Since DTG is a substrate for UGT1A1 and CYP3A4, pharmacokinetic interactions involving co-administration of a UGT1A1 or CYP3A4 inhibitor or inducer could perturb the pharmacokinetics of DTG. Based on the fraction of DTG metabolized, an interaction with UGT1A1 and CYP3A4 inhibitors may be expected if both pathways are fully inhibited (combined f m = 0.72). Ritonavir and atazanavir are HIV PIs that have been co-administered with DTG [Song et al., 2011a] . Both are potent CYP3A4 inhibitors and atazanavir is also a marked UGT1A1 inhibitor. Using a mechanistic static equation (see Materials and Methods) and the estimated f m above, the AUC of DTG was expected to increase by as much as 1.8 to 2.0-fold when co-administered with ritonavir-boosted atazanavir. Indeed, when DTG was co-dosed with 400mg atazanavir in a clinical study, there was a 1.9-and 1.5-fold increase in DTG AUC (0-t) and C max , respectively [Song et al., 2011a] .
When dosed with atazanavir/ritonavir (300/100mg), the DTG AUC (0-t) and C max increased 1.62-fold and 1.34-fold. These data are consistent with UGT1A1 and CYP3A4 being the important This article has not been copyedited and formatted. The final version may differ from this version. In contrast to inhibition of metabolic pathways, metabolic inducers such as rifampin, etravirine, efavirenz and tipranavir need to be considered as they are important agents in the treatment of HIV and other infectious diseases. It is also known that strong activators of human PXR can lead to increased metabolic activity for UGT1A1, CYP3A4 and transporters [Chen et al., 2012] .
Induction of these pathways could increase the systemic clearance of DTG resulting in lower exposures. Both etravirine and efavirenz reduce the AUC (0-t) of DTG by 71% and 57%, respectively [Song et al., 2011c; Song et al., 2011b] . This interaction with DTG is likely the combined effect of UGT and CYP3A4 induction. This is consistent with etravirine and efavirenz causing modest decreases (20 to 40%) in the pharmacokinetics of raltegravir, a sensitive UGT substrate [Kassahun et al., 2007; Iwamoto et al., 2008] . Support for a role of CYP3A4 induction was demonstrated by co-administration of the potent CYP3A4 inhibitors lopinavir/ritonavir or darunavir/ritonavir that counteracted the decrease in DTG exposure by etravirine [Song et al., 2011c] . Alternatively, the decreases in DTG exposure could also involve drug transporters. One interesting possibility is (modest) MRP2 inhibition leading to a partial disruption in the enterohepatic recirculation of DTG; both etravirine and efavirenz are inhibitors of MRP2 [Zembruski et al., 2011b] . This has been reported as an explanation for the reduced exposure of mycophenolate mofetil when co-dosed with cyclosporine A [Hesselink et al., 2005] . Table 3 ), a clinical study demonstrated that DTG had no effect on midazolam's pharmacokinetics , confirming that DTG does not inhibit or induce CYP3A4 in vivo.
The DTG IC 50 values for all transporters examined were >30μM except for OCT2 (discussed below). These IC 50 values are higher than the peak plasma concentration of DTG following a 50 mg daily dose (3.45 μg/mL, ~8μM) , supporting the overall low potential for transporter-mediated drug interactions ([I 1,total ]/IC 50 ; Table 2 ) [Giacomini et al., 2010; Zhang et al., 2008] . Further, the overall drug interaction risk is even lower due to the high plasma protein
binding ( (Table 2 ) [Zhang et al., 2008; Giacomini et al., 2010] . However, based on the [I 2 ]/IC 50 value for BCRP likely being close to 10, there could be a small risk of inhibition of this transporter by DTG. Our findings are consistent with in vitro data reported by Lepist et al. indicating that DTG is a weak or non-inhibitor of Pgp (IC 50s > 90μM), MRP2 (IC 50s > 90μM), and BCRP (IC 50 = 67μM) [Lepist et al., 2011] . Overall, the data support a low potential for DTG to cause clinically significant DDIs with other drugs such as simvastatin, rosuvastatin and atorvastatin (OATP, BCRP and CYP substrates), and metformin (OCT1/2 substrate). A clinical study with tenofovir, an OAT and MRP4 substrate [Ray et al., 2006] , demonstrated no interaction of DTG on tenofovir pharmacokinetics , suggesting that DTG is not an inhibitor of these transporters in vivo.
This article has not been copyedited and formatted. The final version may differ from this version. In contrast to the other transporters discussed, DTG causes notable in vitro inhibition of the renal transporter OCT2 (IC 50 = 1.9μM). As this value is 4-fold lower than the C max of DTG ([I 1,total ]/IC 50 =4.2), a potential interaction exists for compounds that undergo renal secretion via OCT2, such as circulating serum creatinine (a product of muscle turnover) and the antiarrhythmic drug dofetilide. The in vitro OCT2 inhibition data are consistent with the mild 10-14% decreases in serum creatinine clearanceobserved in patients administered DTG [Koteff et al., 2011; vanLunzen et al., 2012] . These mild, reversible changes are similar to other clinical observations with OCT/MATE inhibitors such as dronedarone, AZD0837, and DX-619 [Tschuppert et al., 2007; Schutzer et al., 2010; Sarapa et al., 2007; Imamura et al., 2011] . A clinical study confirmed that the changes in creatinine were not due to DTG altering renal blood flow or renal clearance; therefore, the changes in creatinine serum levels are likely due to the inhibition of the OCT2 transporter [Koteff et al., 2011; Schutzer et al., 2010; Kusuhara et al., 2011] . Caution with concomitant dosing of DTG and dofetilide, a narrow therapeutic index class III anti-arrhythmic agent, is warranted as OCT2 inhibition can significantly reduce its renal clearance as shown by a clinical interaction with cimetidine [Roukoz and Saliba, 2007] .
However, there is less concern for other OCT substrates, such as metformin, as these drugs have larger therapeutic windows compared to dofetilide. In addition, the lack of significant inhibition of OCT1 allows transport of metformin to the liver, its site of action, to maintain its pharmacological effect.
In conclusion, these in vitro studies reveal the low propensity of DTG to cause drug interactions through metabolic or transporter pathways, consistent with the lack of clinical interactions observed to date with DTG. Further, these studies provide a mechanistic explanation for the This article has not been copyedited and formatted. The final version may differ from this version. was incubated for 120 minutes with 150 pmol/mL CYP enzyme or 2 mg/mL HLM. [Zhang et al., 2008; Giacomini et al., 2010] .
b [I 2 ]=477μM using 250mL gastrointestinal volume. **: possible DDI risk based on [I 2 ]>10 as described in [Zhang et al., 2008; Giacomini et al., 2010] c Not calculated; DTG at a concentration of 10 μM inhibited OCT1 by 22%.
d n/a = not applicable; transporter not (highly) expressed in the gastrointestinal tract [Hilgendorf et al., 2007] This article has not been copyedited and formatted. The final version may differ from this version. 
